Listed

PharmaCyte Biotech, Inc.: Form 10-Q/A for the period ended Jul 31, 2011

Filed with the SEC on Sep 20, 2011 and accepted by EDGAR at Sep 20, 2011, 16:37 ET.

Share

Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2011-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2011-05-01 to 2011-07-31$19.8kus-gaap:Revenues
Cost of revenue3 months2011-05-01 to 2011-07-31$15.7kus-gaap:CostOfRevenue
Gross profit3 months2011-05-01 to 2011-07-31$4.1kus-gaap:GrossProfit
Interest expense3 months2011-05-01 to 2011-07-31−$33.4kus-gaap:InterestExpense
Net income3 months2011-05-01 to 2011-07-31−$686.0kus-gaap:NetIncomeLoss
Basic EPS3 months2011-05-01 to 2011-07-31$0.00us-gaap:EarningsPerShareBasic
Operating cash flow3 months2011-05-01 to 2011-07-31−$119.6kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2011-07-31$83.1kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2011-07-31$449.2kus-gaap:AssetsCurrent
Total assetsAt period end2011-07-31$1.6mus-gaap:Assets
Current liabilitiesAt period end2011-07-31$3.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2011-07-31$3.4mus-gaap:Liabilities
Short-term borrowingsAt period end2011-07-31$2.4mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2011-07-31−$2.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001262463-11-000192. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.